Loading news...
WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, announced the recipients of the 2026 Derek Forfang Patient Advocate Award: Edward Drake II, Markesha Grayson, Timmy Nelson, Pesh Patel and Glenda Roberts.
Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and bloating, during 12 weeks of treatment Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and bloating, during 12 weeks of treatment
WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences: Leerink Partners 2026 Global Healthcare Conference Location: Miami, FLPresentation: Tuesday, March 10 at 4:20 p.m.
Michael Raab sold 41,666 shares directly on Feb. 24, 2026, for approximately $261,000 at a weighted-average price of $6.25 per share. The sale represented 2.19% of Raab's direct holdings at the time of the transaction.
Ardelyx, Inc. (NASDAQ: ARDX - Get Free Report) CEO Michael Raab sold 45,982 shares of the firm's stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $5.85, for a total transaction of $268,994.70. Following the sale, the chief executive officer directly owned 1,856,986 shares of the
DAYTONA BEACH, Fla. and WALTHAM, Mass.
Ardelyx, Inc. (NASDAQ: ARDX - Get Free Report) Director David Mott bought 333,333 shares of the business's stock in a transaction on Friday, February 20th. The shares were acquired at an average cost of $5.84 per share, for a total transaction of $1,946,664.72. Following the purchase, the director directly owned 3,302,918 shares in the company, valued
Why Ardelyx's Offensive Strategy Doesn't Move The Needle
Ardelyx, Inc. delivered strong FY 2025 revenue growth, driven by Ibsrela, but missed on earnings due to sharply higher SG&A and R&D costs. Ibsrela's accelerating momentum underpins management's guidance for $410–$430M 2026 revenue and a $1B annual target by 2029, supported by patent protection through 2042. Xphozah revenue is declining and maturing, while heavy operational spend and net losses raise concerns about cost discipline and sustainability.
Ardelyx Inc. (NASDAQ: ARDX) shares are down during Friday's premarket session following a recent financial update for the fourth quarter of 2025.
Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript
Although the revenue and EPS for Ardelyx (ARDX) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ardelyx (ARDX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.02 per share a year ago.
IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs for new IBSRELA indication and next-generation NHE3 inhibitor launched Company is well capitalized to meet current business objectives Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.
Besides Wall Street's top-and-bottom-line estimates for Ardelyx (ARDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Ardelyx, Inc. (NASDAQ: ARDX - Get Free Report) was the recipient of a large decrease in short interest during the month of January. As of January 30th, there was short interest totaling 18,557,299 shares, a decrease of 15.0% from the January 15th total of 21,833,586 shares. Based on an average daily trading volume, of 4,965,903 shares,
Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx (NASDAQ: ARDX - Get Free Report) will likely be announcing its Q4 2025 results after the market closes on Thursday, February 19th. Analysts expect Ardelyx to post earnings of $0.02 per share and revenue of $118.0430 million for the quarter. Individuals are encouraged to explore the company's upcoming Q4 2025 earning overview page for the
WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 19, 2026, at 4:30 p.m.
WALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.